Full-Time

Senior Compliance Officer

Global Monitoring, Auditing and Third-Party Risk Management

Posted on 12/6/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$230.4k - $345.6k/yr

Remote in UK + 1 more

More locations: Pennsylvania, USA

Remote

Category
Legal & Compliance (1)
Required Skills
SAS
SQL
Data Analysis
Excel/Numbers/Sheets
Requirements
  • 10-12 years of relevant pharmaceutical compliance and/or privacy experience in-house, with specific expertise in utilizing data analytics to design and implement a healthcare compliance monitoring program
  • Law degree preferred, but not required
  • Excellent analytics skills and experience with data analysis software (e.g., Excel, SQL, SAS)
  • Extensive experience conducting healthcare compliance audits, including audits of third-party healthcare-related vendors
  • Familiarity with and extensive experience designing and managing a third-party compliance and privacy diligence and monitoring program, particularly for a global pharmaceutical company
  • Solid judgment and business acumen and understanding of business operations, particularly in multinational pharmaceutical organizations
  • Solid understanding of laws and regulations governing the pharmaceutical or healthcare industry both in the US and internationally, including trade sanctions regulations
  • Experience working in a business environment across multiple functions and geographies, with high level of responsiveness and with a strong customer service orientation
  • Experience providing compliance advice and guidance to senior and executive leadership
  • Excellent communication skills, both oral and written, enthusiastic, self-motivated, efficient, able to handle heavy workload; team player, who enjoys working in and supporting a collaborative environment
  • Able to work accurately with an appropriate sense of urgency and function effectively and efficiently in a fast-paced and dynamic environment
  • Strong interpersonal skills, including diplomacy, flexibility and collaboration and the ability to interface effectively throughout all levels of the organization as well as with external parties, and adaptable to circumstances and variety of cultures
  • Effective manager, capable of providing expert direction and driving enthusiasm, creativity, collaboration, and a positive work environment for his/her team
  • 30-40% travel required.
Responsibilities
  • Leads a global team of compliance, data analytics, and monitoring / auditing professionals to support the strategic objectives of the organization and its commitment to compliance and ethics by:
  • Developing, implementing, and enhancing a global compliance and privacy monitoring program, including an effective live monitoring program designed to support our business both in the US and internationally, and with a particular focus on developing and implementing an effective data analytics approach to compliance and privacy monitoring;
  • Developing, implementing, and enhancing the global compliance and privacy audit function, including collaboration with senior leaders in Internal Audit and other departments that regularly audit Jazz business activities such as Quality and Finance and those of our third-party partners; and
  • Developing, implementing and enhancing the compliance and privacy review and on-going monitoring components of the Jazz Third-Party Risk Management program, including collaborating and coordinating with other risk assurance leaders to manage this program, including ERM, Finance / Procurement, and IT.
  • Collect and analyze data to detect global emerging risk areas, deficient controls, fraud, or non-compliance with laws, regulations, and policies. Prepare detailed reports and/or dashboards for the Ethics, Compliance, and Privacy team, as well as key stakeholders, including global leaders of Jazz’s Commercial, R&D, Finance, and other key functions to provide strategic risk information and assessment of the adequacy of compliance controls;
  • Leads the global compliance and privacy risk assessment process, with a particular emphasis on the use of data analytics to inform the process;
  • Manages global transparency reporting process;
  • Serves as a key member of the Ethics, Compliance, and Privacy lead team, coordinating with other lead team members to advance the department’s goals and objectives and to drive consistency in the approach to compliance and ethics across the company;
  • Stays informed on new laws, regulations, and industry trends affecting the company and ensures that those new developments are appropriately reflected in the compliance and privacy risk assessment processes, monitoring and auditing program and third-party risk management
  • Willingly assists Ethics, Compliance, and Privacy Department colleagues with projects and activities in areas outside of his/her primary areas of responsibility as needed to achieve corporate objectives, contribute to a collegial atmosphere and balance workloads.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex generated $1.1B in 2025 sales, up 9% YoY, with patents protected to late 2030s.
  • Q1 2026 revenue hit $1.1B, up 19% YoY, prompting Raymond James target raise to $239 on May 7.
  • Chimerix acquisition adds dordaviprone for H3 K27M-mutant glioma, PDUFA August 18, 2025.

What critics are saying

  • Generic competition erodes Xywav revenue as it replaces Xyrem, decelerating growth to 5.5% annually.
  • Dordaviprone fails FDA approval on August 18, 2025 PDUFA, wasting $935M Chimerix acquisition.
  • $850M exchangeable notes due 2030 dilute equity at $153.05 exchange price amid EPS decline.

What makes Jazz Pharmaceuticals unique

  • Jazz Pharmaceuticals focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Xywav offers 92% less sodium than Xyrem, approved July 21, 2020, for narcolepsy in patients aged 7+.
  • Epidiolex, acquired via $7.2B GW Pharma deal in 2021, treats Lennox-Gastaut and Dravet syndromes.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE